67 results about "Acetylglucosamine" patented technology

The invention discloses recombinant escherichia coli with high yield of N-acetylneuraminic acid and application of the recombinant escherichia coli, and relates to the technical field of biological genetic engineering. The invention relates to a recombinant escherichia coli, which is characterized in that the escherichia coli is taken as a host, and free expression of an N-acetylmannosamine epimerase gene yihS from Streptomyces xiamenensis or an N-acetylmannosamine epimerase gene ce3 from Bacteroides polymorpha and an exogenous N-acetylneuraminic acid lyase gene nano A is carried out; and carrying out recombinant expression on N-acetyl hexosamine 1-kinase nahK, a UDP-N-acetyl glucosamine pyrophosphorylase gene glmU and a UDP-N-acetyl glucosamine-2-epimerase gene neuC in the other synthetic route of the ManNAc. According to the recombinant escherichia coli with high yield of N-acetylneuraminic acid, the yield of N-acetylneuraminic acid can reach 23.08 g / L under a shake flask fermentation condition; a two-stage batch feeding strategy is adopted, the yield of N-acetylneuraminic acid in a 5L fermentation tank reaches 71.25 g / L, the molar conversion rate of GlcNAc reaches up to 57.60%, and the method has the potential of industrial application.

The invention discloses an N-acetylglucosamine transferase AcetRS-K23G and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the N-acetylglucosamine transferase AcetRS-K23G is as shown in SEQ ID NO. 3. The invention further discloses an application of the N-acetylglucosamine transferase AcetRS-K23G in the preparation of the chitosan oligosaccharide. The N-acetylglucosamine transferase AcetRS-K23G disclosed by the invention is obtained by performing mutation modification on the N-acetylglucosamine transferase AcetRS, and can be used for producing the chitosan oligosaccharide with the polymerization degree of 5-7, especially the heptaose, the yield of the heptaose can reach 42.01 mg / L, and the N-acetylglucosamine transferase AcetRS-K23G is an ideal functional enzyme for industrially producing the heptaose. The product spectrum of the N-acetylglucosamine transferase is widened, and the N-acetylglucosamine transferase can be used for preparing high-polymerization-degree chitosan oligosaccharide and has a wide application prospect.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention provides a method for treating autoimmune diseases mediated by regulatory T cell (Treg) programmed necrosis. Specifically, the invention provides application of an O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) accelerant, and the O-linked beta-N-acetylglucosamine glycosylation accelerant is used for preparing a medicine or a preparation for treating programmed necrosis type autoimmune diseases. It is found for the first time that when the O-GlcNAcylation promoter is used for improving the O-GlcNAcylation level of RIPK1 / 3 protein, Treg programmed necrosis can be effectively inhibited, and therefore autoimmune diseases are improved.

The present application belongs to the field of genetic engineering and microbial fermentation technology, and particularly relates to a recombinant Escherichia coli for producing N-acetylglucosamine as well as a construction method and application thereof. The present application takes Escherichia coli as a chassis, knocks out the nagDCABE gene cluster, the manXYZ gene cluster and the serA gene of the genome of the Escherichia coli, and introduces the glmS, GNA1 and serA genes into the Escherichia coli through a vector for expression. The yield of the Escherichia coli for fermenting GlcNAc provided by the present application can reach more than 100 g / L.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

The invention discloses a method for producing oligosaccharide by cooperatively treating aspergillus niger residues through multiple enzymes. The method comprises the following steps: mixing pretreated aspergillus niger residues with hydrochloric acid, carrying out acidolysis wall breaking, and carrying out suction filtration on an obtained wall-broken mixture; carrying out mixed treatment on filtrate obtained by suction filtration with cellulase and beta-glucanase, filtering, and carrying out concentration and alcohol precipitation on supernate to obtain soluble beta-glucan oligosaccharide; performing filter residue enzymolysis on filter residues obtained by suction filtration by using mesoporous silica immobilized chitinase, and recovering the immobilized chitinase after enzymolysis; and filtering the mixed solution subjected to enzymolysis by using the immobilized chitinase, and carrying out alcohol precipitation on the supernate to obtain the N-acetylglucosamine and the chitosan oligosaccharide. According to the method disclosed by the invention, the aspergillus niger residues are jointly treated by adopting multiple enzymes, the yield of N-acetylglucosamine and chitosan oligosaccharide reaches 85.1%-88.5%, and the yield of beta-glucosamine oligosaccharide reaches 86.7%-89.3%. The invention provides a brand new route for producing various oligosaccharides by utilizing solid waste aspergillus niger residues in the fermentation industry.

A method for producing modified cells lacking mannosyl(alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosamine transferase 1 ("MGAT1") activity is provided. The MGAT1 activity-deficient CHO cell line produced by this method is also provided. A method for producing glycoproteins is further disclosed.

The application discloses a purification method of plant exosome, and belongs to the technical field of biological separation. The method comprises the following steps: obtaining plant juice or tissue extract, pre-treating the plant juice or tissue extract through coarse filtration and centrifugation, incubating the plant juice or tissue extract with magnetic microspheres modified with carboxyl or epoxy groups in a buffer containing calcium ions, capturing the complex by using an external magnetic field, washing the complex, eluting the complex by using a competitive elution buffer containing N-acetylglucosamine, and further purifying the complex by using a size exclusion chromatography column to obtain the plant exosome. The exosome is specifically captured by the magnetic microspheres, and the double purification strategies of competitive elution and size exclusion chromatography are combined, so that the recovery rate and purity of the exosome are significantly improved. The method is simple in operation, short in time consumption, good in repeatability, and suitable for the large-scale preparation of exosomes of various plant sources. The plant-derived exosome prepared by the method can be applied to the fields of drug delivery systems, cosmetics, respiratory health and sensory health product development.

The invention discloses an N-acetylglucosamine transferase AcetRS-R346T-K23V and an application thereof, and belongs to the technical field of functional enzymes. The amino acid sequence of the N-acetylglucosamine transferase AcetRS-R346T-K23V is as shown in SEQ ID NO.7. The invention also discloses the application of the N-acetylglucosamine transferase AcetRS-R346T-K23V in preparation of chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V disclosed by the invention is extremely high in specificity of producing the chitohexaose, and the chitohexaose accounts for 93.21% in an enzymolysis product of the N-acetylglucosamine transferase AcetRS-R346T-K23V; moreover, the enzymolysis product only contains two kinds of chitosan oligosaccharides and does not contain chitotetraose and chitoheptaose, which is extremely beneficial to the subsequent efficient separation of chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V disclosed by the invention can be used for efficiently producing the chitohexaose, and has a good application prospect.

The invention provides a drug carrier based on N-acetylglucosamine, a drug preparation and a preparation method. The drug carrier based on N-acetylglucosamine comprises N-acetylglucosamine and a cross-linking agent, the cross-linking agent is a compound with an aldehyde group or a ketone group, and the aldehyde group or the ketone group reacts with the deacetylated N-acetylglucosamine to generate one or more of a hydrazide bond, a hydrazone bond or an imine bond. The drug carrier based on N-acetylglucosamine shows remarkable advantages in the aspects of particle size distribution, drug loading capacity, encapsulation efficiency and cumulative drug release rate.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The invention relates to the technical field of functional food, in particular to an electrolyte composition beneficial to joint injury repair after exercise and a preparation method of the electrolyte composition. The electrolyte composition is mainly prepared from the following raw materials in parts by mass: 0.1 to 2 percent of N-acetylglucosamine, 0.05 to 0.5 percent of cartilage extract, 0.05 to 0.5 percent of enzymolysis bone meal, 0.01 to 0.05 percent of milk mineral salt, 0.1 to 1 percent of collagen peptide, 0.01 to 0.3 percent of vitamin and 0.03 to 0.3 percent of electrolyte. The nano hydrated milk mineral salt is adopted, the absorption efficiency of elements such as calcium and phosphorus in a body is improved, and the electrolyte composition is prepared by combining components such as N-acetylglucosamine and the cartilage extract, so that joint inflammation and cartilage injury caused by exercise are effectively improved while water and electrolyte are supplemented, and the activity of joints and exercises is improved. The electrolyte composition is good in taste, high in stability and suitable for joint protection and nutrition supplement after exercise.

The invention relates to the technical field of microbial fermentation and enzyme engineering, and in particular relates to a strain Precottula equi GXAS 17-2 for high yield of chitin deacetylase as well as a fermentation culture medium and application thereof, the preservation number of the strain Precottula equi GXAS 17-2 is GDMCC NO: 67488, and the strain is separated from mangrove forest soil and can efficiently produce enzyme in the culture medium taking N-acetylglucosamine (GlcNAc) as an inducer. The enzyme activity is remarkably improved by optimizing culture medium components (3% of colloidal chitin, 10% of yeast powder and 0.3% of GlcNAc) and culture conditions (30 DEG C, 180 rpm, pH 7 and 48 h). The method has the advantages of high induction efficiency, green process, stable enzyme activity and the like, and is suitable for chitin degradation and chitosan green preparation industry.

The invention discloses a 2-acetylglucosamine potassium sulfate salt compound as well as a preparation method and application thereof. The compound has a structure as shown in a formula I. The compound shown in the formula I has biological activity for preventing and / or treating tumors. I

The invention relates to the technical field of biology, and discloses a recombinant N-acetylglucosamine-1-phosphate uridine transferase (GlmU) mutant and a preparation method thereof. The sequence of the recombinase is formed by connecting an N-acetylglucosamine-1-uridine phosphate transferase (GlmU) mutant (L113V-V172I) from Azotobacter chroococcum, an N-terminal histidine tag (His-tag) and a small ubiquitin-like modified protein tag (SUMO-tag) in series. The invention further discloses a preparation method of the recombinase. Compared with a recombinant wild type N-acetylglucosamine-1-uridine phosphate transferase with the same source, the recombinant N-acetylglucosamine-1-uridine phosphate transferase mutant has higher activity which is 1.5 times of that of the recombinant wild type and higher stability, and the residual activity of the mutant is 66.5% after the mutant is placed at room temperature for 5 days, so that the mutant has a good application prospect in the field of N-acetylglucosamine-1-uridine phosphate transferase. And the soluble expression quantity of the recombinant mutant N-acetylglucosamine-1-uridine phosphate transferase is increased by 5 times.

Composition for improving inflammation in osteoarthritis, characterized in that the composition comprises the following components, measured in parts by weight: 1 to 5 parts by weight of N-acetylglucosamine and 0.1 to 2 parts by weight of calcium element in a calcium source.

This invention provides a composition with anti-inflammatory, acne-reducing, and oil-controlling effects, and its preparation method, comprising active functional components and excipients; wherein the active functional components are tea tree oil, benzoyl peroxide, azelaic acid, quaternary ammonium salt-73, niacinamide, zinc gluconate, retinaldehyde, salicylic acid, licorice extract, purslane extract, capryloyl glycine, acetylglucosamine, and asiaticoside; the excipients include skin conditioning agents, moisturizers, nonionic emulsifiers, and skin-nourishing agents. This invention, through targeted synergistic system design, covers the entire pathogenesis mechanism of acne, achieving synergistic effects of antibacterial acne reduction, oil control, keratinization unblocking, anti-inflammatory repair, and microecological balance; simultaneously, through gradient feeding, liquid crystal emulsification, and low-temperature activation locking preparation methods, the stability of active ingredients is preserved to the greatest extent, solving the industry pain points of traditional acne products where efficacy and gentleness cannot be simultaneously achieved, active ingredients are easily deactivated, and acne is prone to recurrence. It can be widely applied to the preparation of various acne-reducing and oil-controlling skin care products.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.

The application discloses N-acetylglucosamine transferase AcetRS-R346T-K23V and application thereof, and belongs to the technical field of functional enzymes. The amino acid sequence of the N-acetylglucosamine transferase AcetRS-R346T-K23V is shown as SEQ ID NO. 7, and the application thereof in preparing chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V has very high specificity in producing chitohexaose, and the proportion of chitohexaose in the enzymatic product can reach 93.21%; moreover, the enzymatic product only contains two chitooligosaccharides, and does not contain chitotetraose and chitoseptaoose, which is extremely favorable for efficient separation of subsequent chitohexaose. The N-acetylglucosamine transferase AcetRS-R346T-K23V can be used for efficiently producing chitohexaose, and has a good application prospect.

The invention relates to a beta-1, 3-acetyl glucosamine transferase mutant and application thereof in synthesis of LNT II, the mutant takes wild beta-1, 3-acetyl glucosamine transferase with an amino acid sequence as shown in SEQ ID NO.1 as a parent sequence, and amino acid residues at the 143rd, 146th, 156th, 159th, 160th and 230th sites of the parent sequence are subjected to one or more site mutation. The mutant provided by the invention can significantly improve the yield of LNT II, and lays an important foundation for biosynthesis of LNT and LNnT.

This invention discloses a nutritional composition and preparation method for improving joint health in senior pets. The nutritional composition comprises: N-acetylglucosamine, chondroitin sulfate, methanesulfonylmethane, unsaponifiable avocado and soybean extract, hyaluronic acid, curcumin microcapsule powder, and high-concentration fish oil. This invention uses a lipid / polysaccharide bilayer microcapsule structure to encapsulate curcumin and fish oil, and prepares the product through low-temperature homogenization, spray drying, and granulation processes. The composition of this invention works synergistically through multiple pathways, simultaneously exerting effects on three key levels: anti-inflammation, lubrication, and cartilage repair. It can significantly inhibit joint inflammation, improve joint lubrication, and promote cartilage repair. This invention solves the problems of existing pet joint products, such as single pathways of action, low stability and bioavailability of lipid-soluble active ingredients, and lack of overall formulation optimization tailored to the characteristics of aging pets. It is suitable for daily joint health maintenance or adjunctive treatment in middle-aged and senior dogs and cats.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain for synthesizing N-acetylglucosamine as well as a construction method and application thereof. The engineering bacterium takes escherichia coli as an original strain, and is obtained through the following multi-level metabolic engineering transformation: (1) knocking out a gene cluster nagEBACD and a gene cluster manXYZ; (2) integrating a target gene expression cassette driven by a constitutive promoter at a stable expression site of the genome; (3) knocking out poxB, ldhA, manA and murQ; and (4) improving the expression level of the endogenous gene acs through promoter engineering, and introducing the gene glf. According to the invention, through reasonable design and regulation of a metabolic pathway of host bacteria, on the premise of avoiding use of IPTG, lactose or xylose and other exogenous inducers, autonomous stable expression of key metabolic genes is realized, so that the production cost is reduced, the fermentation process is simplified, and the controllability and batch stability of the fermentation process are improved.

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

The invention provides a composition for promoting joint health as well as a preparation method and application thereof, and the composition comprises the following components in parts by weight: 2-20 parts of bovine bone collagen peptide powder, 2-15 parts of N-acetylglucosamine, 2-15 parts of a calcium compound, 0.1-3 parts of avocado powder and 0.1-3 parts of rhizoma polygonati powder. The composition disclosed by the invention can play a role in promoting cartilage repair, resisting inflammation and the like, achieves the purpose of promoting joint health, and has a relatively good application prospect.

This invention discloses a method for in vitro synthesis of natural H11 glycopeptides from *Haemaphysalis contortus*, belonging to the field of biomedicine. The method includes the following steps: preparing a glycosyl donor compound using sialic acid glycopeptide SGP as a raw material; activating the glycosyl donor to a glycooxazoline; transglycosylation of the glycooxazoline with an H11 glycopeptide chain carrying acetylglucosamine at the N site to obtain the glycopeptide compound; catalyzing the glycopeptide compound with core fucosyltransferase 8, *Haemaphysalis contortus*-derived galactosyltransferase 1, β-1,4-galactosyltransferase, and fucosyltransferase to obtain corresponding glycosyl modifications from the donor, yielding a natural *Haemaphysalis contortus* H11 glycopeptide containing an LDNF structure and a *Gal(β1,4)Fuc* nematode-specific epitope. This invention can accurately mimic the nematode-specific glycosylation modification of natural H11, with high product uniformity, and can provide an antigen source for vaccine development for *Haemaphysalis contortus* disease.

Embodiments of the present invention provides recombinant systems, methods, and compositions for the biological production of Testosteronan (Testan), a linear α-(1→4)-linked glucuronic acid–N-acetylglucosamine polysaccharide. Microbial hosts engineered to express full-length CtTS, N-terminal truncation variants (including d64-CtTS), or the Pseudomonas CIPTS homolog synthesize high–molecular-weight Testan (≥800 kDa) with low polydispersity. Structural analysis by ¹H NMR and 2D HSQC demonstrates that all recombinant enzymes produce Testan that is chemically indistinguishable from native polymer. Purification using ultrafiltration and strong-anion exchange chromatography yields highly defined molecular-weight fractions, including monodisperse populations (PDI ~1.02). The invention further provides sulfated derivatives of Testan produced via aqueous sulfation methods, as well as Testan and functionalized Testan compositions useful for chromatographic stationary phases, biomaterial scaffolds, and chemically modifiable polymer platforms. These systems provide the first scalable, fermentation-based production methods for Testan and Testan-derived materials.

Described herein is a beta-glycoside of structural formula (I) wherein X1 or X2 is-C (= O) OR, R is an alkyl group comprising from 1 to 6 (1 to 4) carbon atoms, and Y is a monovalent sugar selected from the group consisting of beta-D-glucose, beta-D-galactose, beta-D-glucuronic acid, N-acetylglucosamine or galactosamine, where when X1 is-C (= O) OR then X2 is-H, and when X2 is-C (= O) OR then X1 is-H. Such beta-glycosides can be used as indicators, such as biological indicators. (I)

This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of fermentation of metabolically engineered microorganisms. The disclosure describes engineered microorganisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These microorganisms can dephosphorylate N-acetylglucosamine-6-phopshate to N-acetyl glucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These microorganisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate. Furthermore, provided is a method for the large scale in vivo synthesis of sialylated compounds, by culturing a microorganism in a culture medium, optionally comprising an exogenous precursor such as, but not limited to lactose, lactoNbiose, N-acetyllactosamine and / or an aglycon, wherein the microorganism intracellularly dephosphorylates N-acetylglucosamine-6-phopshate to N-acetylglucosamine, converts N-acetylglucosamine to N-acetylmannosamine and convert the latter further to N-acetyl-neuraminate.